Biogen (NASDAQ:BIIB) Releases Earnings Results, Beats Estimates By $1.13 EPS

Thursday, July 22, 2021 | MarketBeat

Biogen (NASDAQ:BIIB) posted its earnings results on Thursday. The biotechnology company reported $5.68 EPS for the quarter, beating analysts' consensus estimates of $4.55 by $1.13, RTT News reports. The firm had revenue of $2.78 billion during the quarter, compared to the consensus estimate of $2.61 billion. Biogen had a return on equity of 42.04% and a net margin of 23.89%. The company's quarterly revenue was down 24.6% compared to the same quarter last year. During the same period in the prior year, the company earned $10.26 EPS. Biogen updated its FY21 guidance to $17.50-19.00 EPS.

Shares of Biogen stock opened at $324.99 on Thursday. The stock has a market capitalization of $48.93 billion, a price-to-earnings ratio of 17.07, a P/E/G ratio of 1.59 and a beta of 0.44. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.75 and a current ratio of 2.12. Biogen has a 12 month low of $223.25 and a 12 month high of $468.55. The company's fifty day moving average price is $333.47.

A number of research firms have recently commented on BIIB. HC Wainwright increased their target price on Biogen from $305.00 to $452.00 and gave the company a "buy" rating in a research report on Tuesday, June 8th. Cowen upgraded Biogen from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $225.00 to $450.00 in a research report on Monday, June 7th. The Goldman Sachs Group raised their price target on Biogen from $246.00 to $436.00 and gave the stock a "neutral" rating in a research report on Monday, June 14th. Piper Sandler upgraded Biogen from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $384.00 to $450.00 in a research report on Friday, June 18th. Finally, Oppenheimer raised their price target on Biogen from $300.00 to $325.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 18th. Fourteen equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Biogen presently has a consensus rating of "Buy" and a consensus price target of $385.10.

In other Biogen news, insider Alfred Sandrock sold 7,672 shares of Biogen stock in a transaction dated Monday, June 7th. The stock was sold at an average price of $440.00, for a total value of $3,375,680.00. Following the transaction, the insider now owns 2,919 shares in the company, valued at $1,284,360. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian S. Posner sold 360 shares of Biogen stock in a transaction dated Friday, June 4th. The shares were sold at an average price of $274.17, for a total value of $98,701.20. Following the completion of the transaction, the director now owns 7,400 shares in the company, valued at approximately $2,028,858. The disclosure for this sale can be found here. Company insiders own 0.54% of the company's stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.

Read More: What causes a recession?

Earnings History for Biogen (NASDAQ:BIIB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Biogen right now?

Before you consider Biogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.

While Biogen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.